Abstract
Hyperglycemia commonly occurs in patients who are acutely ill, in a variety of clinical situations. Generally, moderate hyperglycemia in critically ill patients was thought to be beneficial; however, the degree of hyperglycemia on admission and the duration of hyperglycemia during critical illness are now recognized markers of adverse outcome. The use of insulin therapy to maintain normoglycemia for at least a few days improves survival and reduces morbidity in patients who are in a surgical intensive care unit (ICU), as shown by a large, randomized, controlled study. These results were recently confirmed by two studies—a randomized, controlled study of patients in a medical ICU, and a prospective, observational study of a heterogeneous patient population admitted to a mixed medical and surgical ICU. Results of multicenter trials that investigated tight blood-glucose control in critically ill patients are, however, still lacking. While we await those multicenter results, the current evidence favors the control of blood glucose levels in the ICU. Indeed, the studies showed that many lives are saved with this intervention, despite an increased incidence of hypoglycemia. Prevention of glucose toxicity by strict glycemic control (but also other metabolic and nonmetabolic effects of insulin) contribute to these clinical benefits.
Key Points
-
Hyperglycemia is common in acutely ill patients, diabetic or not, from a variety of different clinical settings
-
The upon-admission degree of hyperglycemia and the duration of hyperglycemia during critical illness have been increasingly recognized as markers of adverse outcome
-
Maintenance of normoglycemia with insulin therapy over at least a few days improves survival and reduces morbidity of patients in either surgical or medical intensive care units
-
Although the risk of hypoglycemia is increased with intensive insulin therapy, there is now evidence that brief hypoglycemia, diagnosed and treated promptly, does not cause early nor late mortality
-
The risk of hypoglycemia should not be used as a reason not to apply intensive insulin therapy
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Van den Berghe G et al. (2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345: 1359–1367
Rovlias A and Kotsou S (2000) The influence of hyperglycemia on neurological outcome in patients with severe head injury. Neurosurgery 46: 335–342
Yendamuri S et al. (2003) Admission hyperglycemia as a prognostic indicator in trauma. J Trauma 55: 33–38
Bochicchio GV et al. (2005) Persistent hyperglycemia is predictive of outcome in critically ill trauma patients. J Trauma 58: 921–924
Capes SE et al. (2000) Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 355: 773–778
Capes SE et al. (2001) Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 32: 2426–2432
Krinsley JS (2003) Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 78: 1471–1478
Van den Berghe G et al. (2005) Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 64: 1348–1353
Ingels C et al. (2006) Strict blood glucose control with insulin during intensive care after cardiac surgery: impact on 4-years survival, dependency on medical care, and quality-of-life. Eur Heart J 27: 2716–2724
Krinsley JS (2004) Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 79: 992–1000
Grey NJ and Perdrizet GA (2004) Reduction of nosocomial infections in the surgical intensive-care unit by strict glycemic control. Endocr Pract 10 (Suppl 2): S46–S52
Van den Berghe G et al. (2006) Intensive insulin therapy in the medical ICU. N Engl J Med 354: 449–461
Van den Berghe G et al. (2006) Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. Diabetes 55: 3151–3159
Van den Berghe G et al. (2006) Analysis of healthcare resource utilization with intensive insulin therapy in critically ill patients. Crit Care Med 34: 612–616
Krinsley JS and Jones RL (2006) Cost analysis of intensive glycemic control in critically ill adult patients. Chest 129: 644–650
The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986
UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood–glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853
Vriesendorp TM et al. (2006) Predisposing factors for hypoglycemia in the intensive care unit. Crit Care Med 34: 96–101
Vriesendorp TM et al. (2006) Evaluation of short-term consequences of hypoglycemia in an intensive care unit. Crit Care Med 34: 2714–2718
Watt MJ et al. (2001) Adrenaline increases skeletal muscle glycogenolysis, pyruvate dehydrogenase activation and carbohydrate oxidation during moderate exercise in humans. J Physiol 534: 269–278
Wolfe RR (1979) Glucose metabolism in severely burned patients. Metabolism 28: 1031–1039
Wolfe RR et al. (1987) Effect of severe burn injury on substrate cycling by glucose and fatty acids. N Engl J Med 317: 403–408
Stephens JM et al. (1992) Differential regulation of glucose transporter gene expression in adipose tissue or septic rats. Biochem Biophys Res Commun 183: 417–422
Virkamaki A and Yki-Jarvinen H (1994) Mechanisms of insulin resistance during acute endotoxemia. Endocrinology 134: 2072–2078
McCowen KC et al. (2001) Stress-induced hyperglycemia. Crit Care Clin 17: 107–124
Meszaros K et al. (1987) Contribution of different organs to increased glucose consumption after endotoxin administration. J Biol Chem 262: 10965–10970
Van den Berghe G et al. (2003) Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 31: 359–366
Finney SJ et al. (2003) Glucose control and mortality in critically ill patients. JAMA 290: 2041–2047
Mesotten D et al. (2004) Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. J Clin Endocrinol Metab 89: 219–226
Mesotten D et al. (2002) Regulation of insulin-like growth factor binding protein-1 during protracted critical illness. J Clin Endocrinol Metab 87: 5516–5523
Klip A et al. (1994) Regulation of expression of glucose transporters by glucose: a review of studies in vivo and in cell cultures. FASEB J 8: 43–53
Van den Berghe G (2004) How does blood glucose control with insulin save lives in intensive care? J Clin Invest 114: 1187–1195
Gosmanov AR et al. (2006) De novo emergence of insulin-stimulated glucose uptake in human aortic endothelial cells incubated with high glucose. Am J Physiol Endocrinol Metab 290: E516–E522
Pekala P et al. (1990) Regulation of hexose transport in aortic endothelial cells by vascular permeability factor and tumor necrosis factor-α, but not by insulin. J Biol Chem 265: 18051–18054
Shikhman AR et al. (2001) Cytokine regulation of facilitated glucose transport in human articular chondrocytes. J Immunol 167: 7001–7008
Quinn LA and McCumbee WD (1998) Regulation of glucose transport by angiotensin II and glucose in cultured vascular smooth muscle cells. J Cell Physiol 177: 94–102
Clerici C and Matthay MA (2000) Hypoxia regulates gene expression of alveolar epithelial transport proteins. J Appl Physiol 88: 1890–1896
Sanchez-Alvarez R et al. (2004) Endothelin-1 stimulates the translocation and upregulation of both glucose transporter and hexokinase in astrocytes: relationship with gap junctional communication. J Neurochem 89: 703–714
Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813–820
Giugliano D et al. (1996) Oxidative stress and diabetic vascular complications. Diabetes Care 19: 257–267
West IC (2000) Radicals and oxidative stress in diabetes. Diabet Med 17: 171–180
Aulak KS et al. (2004) Dynamics of protein nitration in cells and mitochondria. Am J Physiol Heart Circ Physiol 286: H30–H38
Vanhorebeek I et al. (2005) Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet 365: 53–59
Hansen TK et al. (2003) Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 88: 1082–1088
Weekers F et al. (2003) Metabolic, endocrine, and immune effects of stress hyperglycemia in a rabbit model of prolonged critical illness. Endocrinology 144: 5329–5338
Ellger B et al. (2006) Survival benefits of intensive insulin therapy in critical illness: impact of maintaining normoglycemia versus glycemia-independent actions of insulin. Diabetes 55: 1096–1105
Jeschke MG et al. (2004) Insulin treatment improves the systemic inflammatory reaction to severe trauma. Ann Surg 239: 553–560
Black CT et al. (1990) Short-term hyperglycemia depresses immunity through nonenzymatic glycosylation of circulating immunoglobulin. J Trauma 30: 830–832
Nielson CP and Hindson DA (1989) Inhibition of polymorphonuclear leukocyte respiratory burst by elevated glucose concentrations in vitro . Diabetes 38: 1031–1035
Perner A et al. (2003) High glucose impairs superoxide production from isolated blood neutrophils. Intensive Care Med 29: 642–645
Lanza-Jacoby S et al. (1992) Disturbances in the composition of plasma lipoproteins during gram-negative sepsis in the rat. Biochim Biophys Acta 1124: 233–240
Khovidhunkit W et al. (2000) Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 181 (Suppl 3): S462–S472
Carpentier YA and Scruel O (2002) Changes in the concentration and composition of plasma lipoproteins during the acute phase response. Curr Opin Clin Nutr Metab Care 5: 153–158
Harris HW et al. (1990) Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest 86: 696–702
Langouche L et al. (2005) Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest 115: 2277–2286
Siroen MP et al. (2005) Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: a possible explanation of reduced morbidity and mortality? Crit Care Med 33: 504–510
Das UN (2003) Insulin: an endogenous cardioprotector. Curr Opin Crit Care 9: 375–383
Mehta SR et al. (2005) Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 293: 437–446
Malmberg K et al. (2005) Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 26: 650–661
Gao F et al. (2002) Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 105: 1497–1502
Jonassen AK et al. (2001) Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 89: 1191–1198
Bothe W et al. (2004) Glucose-insulin-potassium in cardiac surgery: a meta-analysis. Ann Thorac Surg 78: 1650–1657
Vanhorebeek I et al. (2006) Cortisol response to critical illness: effect of intensive insulin therapy. J Clin Endocrinol Metab 91: 3803–3813
Acknowledgements
The work was supported by research grants from the Katholieke Universiteit Leuven and the Fund for Scientific Research. L Langouche and I Vanhorebeek are supported by the Fund for Scientific Research, Flanders, Belgium.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G Van den Berghe holds an unrestrictive Katholieke Universiteit Leuven Novo Nordisk Chair of Research. The other authors declared they have no competing interests.
Rights and permissions
About this article
Cite this article
Langouche, L., Vanhorebeek, I. & Van den Berghe, G. Therapy Insight: the effect of tight glycemic control in acute illness. Nat Rev Endocrinol 3, 270–278 (2007). https://doi.org/10.1038/ncpendmet0426
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0426
This article is cited by
-
Towards a fasting-mimicking diet for critically ill patients: the pilot randomized crossover ICU-FM-1 study
Critical Care (2020)
-
Guida pratica alla prevenzione e gestione dell’infezione da COVID-19 nelle persone con diabete
L'Endocrinologo (2020)
-
How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT
Bone Marrow Transplantation (2016)
-
Clinical review: Glucose control in severely burned patients - current best practice
Critical Care (2013)
-
Hyperglycaemia and apoptosis of microglial cells in human septic shock
Critical Care (2011)